罗欣药业(002793) - 2025 Q1 - 季度业绩预告

Financial Performance - The company expects a net profit attributable to shareholders of between 5 million and 7 million RMB, compared to a loss of 36.66 million RMB in the same period last year[3]. - The net profit after deducting non-recurring gains and losses is projected to be between 500,000 and 700,000 RMB, compared to a loss of 38.96 million RMB last year[3]. - Basic earnings per share are expected to be between 0.01 RMB per share, recovering from a loss of 0.03 RMB per share in the previous year[3]. Market Development - The increase in market share for the innovative drug Tegoprazan is attributed to the steady progress of the commercial team's promotion and hospital access efforts[5]. Cash Flow and Debt Management - The company has improved its operating cash flow and reduced bad debt losses through a special collection of receivables during the reporting period[5]. Earnings Forecast - The financial data in the earnings forecast has not been audited by the accounting firm, and the final figures will be disclosed in the Q1 2025 report[4]. - The company emphasizes the importance of cautious decision-making for investors due to the preliminary nature of the earnings forecast[6].